-
EP3617198
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3617198
| EP3617198 - GUANIDINE DERIVATIVE [Right-click to bookmark this link] | Status | The patent has been granted Status updated on 22.09.2023 Database last updated on 14.06.2024 | |
| Former | Grant of patent is intended Status updated on 14.05.2023 | ||
| Former | Examination is in progress Status updated on 12.11.2021 | ||
| Former | Request for examination was made Status updated on 31.01.2020 | ||
| Former | The international publication has been made Status updated on 03.11.2018 | Most recent event Tooltip | 17.05.2024 | Lapse of the patent in a contracting state New state(s): PL | published on 19.06.2024 [2024/25] | Applicant(s) | For all designated states Lunan Pharmaceutical Group Corporation No.209, Hongqi Road Linyi, Shandong 276006 / CN | [2020/10] | Inventor(s) | 01 /
ZHANG, Guimin No. 209 Hongqi Road Linyi Shandong 276006 / CN | 02 /
YAO, Jingchun No. 209 Hongqi Road Linyi Shandong 276006 / CN | 03 /
REN, Yushan No. 209 Hongqi Road Linyi Shandong 276006 / CN | [2020/10] | Representative(s) | Lavoix Bayerstraße 83 80335 München / DE | [2023/43] |
| Former [2020/10] | Lavoix Bayerstrasse 83 80335 München / DE | Application number, filing date | 18790575.7 | 27.04.2018 | [2020/10] | WO2018CN84923 | Priority number, date | CN201710288663 | 27.04.2017 Original published format: CN201710288663 | [2020/10] | Filing language | ZH | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2018196861 | Date: | 01.11.2018 | Language: | ZH | [2018/44] | Type: | A1 Application with search report | No.: | EP3617198 | Date: | 04.03.2020 | Language: | EN | [2020/10] | Type: | B1 Patent specification | No.: | EP3617198 | Date: | 25.10.2023 | Language: | EN | [2023/43] | Search report(s) | International search report - published on: | CN | 01.11.2018 | (Supplementary) European search report - dispatched on: | EP | 26.11.2020 | Classification | IPC: | C07D271/08, A61K31/4245, A61P35/00, A61P31/00, A61P25/28, A61P27/12, A61P25/24, A61P25/22, A61P31/04, A61P31/10, A61P31/14 | [2021/01] | CPC: |
A61P31/00 (EP);
C07D271/08 (EP,CN,KR,US);
A61K31/4245 (EP,KR);
A61P25/22 (EP,CN);
A61P25/24 (EP,CN,KR);
A61P25/28 (EP,CN,KR);
A61P27/02 (EP);
A61P27/12 (EP,CN);
A61P31/04 (EP,CN);
A61P31/10 (EP,CN);
A61P31/12 (EP,CN);
A61P33/00 (EP,CN);
|
| Former IPC [2020/10] | C07D271/08, A61K31/4245, A61P25/28, A61P27/02, A61P35/00 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/10]
| Title | German: | GUANIDINDERIVAT | [2020/10] | English: | GUANIDINE DERIVATIVE | [2020/10] | French: | DÉRIVÉ DE GUANIDINE | [2020/10] | Entry into regional phase | 22.11.2019 | Translation filed | 22.11.2019 | National basic fee paid | 22.11.2019 | Search fee paid | 22.11.2019 | Designation fee(s) paid | 22.11.2019 | Examination fee paid | Examination procedure | 22.11.2019 | Examination requested [2020/10] | 15.06.2021 | Amendment by applicant (claims and/or description) | 16.11.2021 | Despatch of a communication from the examining division (Time limit: M04) | 16.03.2022 | Reply to a communication from the examining division | 24.06.2022 | Despatch of a communication from the examining division (Time limit: M04) | 24.10.2022 | Reply to a communication from the examining division | 15.05.2023 | Communication of intention to grant the patent | 14.09.2023 | Fee for grant paid | 14.09.2023 | Fee for publishing/printing paid | 14.09.2023 | Receipt of the translation of the claim(s) | Fees paid | Renewal fee | 30.03.2020 | Renewal fee patent year 03 | 24.03.2021 | Renewal fee patent year 04 | 25.03.2022 | Renewal fee patent year 05 | 22.03.2023 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HR | 25.10.2023 | PL | 25.10.2023 | RS | 25.10.2023 | NO | 25.01.2024 | GR | 26.01.2024 | IS | 25.02.2024 | [2024/25] |
| Former [2024/24] | HR | 25.10.2023 | |
| RS | 25.10.2023 | ||
| NO | 25.01.2024 | ||
| GR | 26.01.2024 | ||
| IS | 25.02.2024 | ||
| Former [2024/20] | GR | 26.01.2024 | |
| IS | 25.02.2024 | Documents cited: | Search | [A]WO2010005958 (INCYTE CORP [US], et al) [A] 1-15* claims 1-15, 24, 27-166; compounds 1, 3, 5, 7, 9, 11, 13, 15, 18 *; | [XPA]WO2018072697 (SHANGHAI PHARMACEUTICALS HOLDING CO LTD [CN]) [XP] 1-4,7-10,13-15 * examples I-20, I-141, I-181, I-182; claims 1-18 * [A] 5,6,11,12 | International search | [A]WO2015119944 (INCYTE CORP [US], et al) [A] 1-30* , entire document, especially pages 3 and 4 *; | [A]WO2016155545 (JIANGSU HENGRUI MEDICINE CO [CN], et al) [A] 1-30 * , entire document, especially pages 2 and 3 *; | [PX]WO2018072697 (SHANGHAI PHARMACEUTICALS HOLDING CO LTD [CN]) [PX] 1, 3-5, 13-18, 20-30 * , description, pages 1, 23, 121, 126, 127 and 145 * | by applicant | - MUNN DHZHOU MATTWOOD JT et al., "Prevention of allogeneic fetal rejection by tryptophan catabolism", Scienice, (19980000), vol. 281, no. 5380, doi:10.1126/science.281.5380.1191, pages 1191 - 3, XP002147184 DOI: http://dx.doi.org/10.1126/science.281.5380.1191 | - JIA YUNLONGWANG YU, Chinese Journal of Cancer Biotherapy, (20040000), vol. 21, no. 6, pages 693 - 7 | - KONG LINGLEIKUANG CHUNXIANGYANG QING, Chinese Journal of Medicinal Chemistry, (20090000), vol. 19, no. 2, pages 147 - 154 | - TAKIKAWA OKUROIWA TYAMAZAKI F et al., J. Biol. Chem., (19880000), vol. 263, pages 2041 - 2048 |